普莱柯所属申万行业为：农林牧渔-动物保健Ⅱ-动物保健Ⅲ。所属概念板块包括：动物疫苗、禽流感药 物、知识产权、宠物经济、小盘等。 截至6月30日，普莱柯股东户数1.80万，较上期增加4.27%；人均流通股19234股，较上期减少4.09%。 2025年1月-6月，普莱柯实现营业收入5.59亿元，同比增长15.79%；归母净利润1.16亿元，同比增长 57.12%。 分红方面，普莱柯A股上市后累计派现10.57亿元。近三年，累计派现5.00亿元。 机构持仓方面，截止2025年6月30日，普莱柯十大流通股东中，国泰中证畜牧养殖ETF（159865）位居 第七大流通股东，持股344.99万股，相比上期增加14.14万股。 责任编辑：小浪快报 9月8日，普莱柯盘中上涨2.01%，截至09:53，报14.74元/股，成交2765.57万元，换手率0.55%，总市值 51.01亿元。 资金流向方面，主力资金净流入102.68万元，特大单买入156.68万元，占比5.67%，卖出0.00元，占比 0.00%；大单买入474.59万元，占比17.16%，卖出528.59万元，占比19.11%。 普莱柯今年以来股价涨19.21% ...

Core Viewpoint - The report highlights the strong performance of the pet segment and the impact of new product launches on the company's revenue growth, leading to an "overweight" rating for the company. Group 1: Financial Performance - In the first half of 2025, the company achieved operating revenue of 559 million yuan, a year-on-year increase of 15.79% [1] - The net profit attributable to shareholders reached 116 million yuan, up 57.12% year-on-year, while the net profit after deducting non-recurring gains and losses was 100 million yuan, reflecting a growth of 50.79% [1] - The net cash flow from operating activities was 195 million yuan, showing a significant increase of 305.09% year-on-year [1] - In Q2 2025, the company reported operating revenue of 281 million yuan, a year-on-year increase of 13.38%, and a net profit of 63 million yuan, up 35.67% year-on-year [1] Group 2: Product Performance - Revenue from various product segments in H1 2025 included: - Pig vaccines: 131 million yuan, down 11.49% year-on-year - Poultry vaccines and antibodies: 259 million yuan, up 30.01% year-on-year - Ruminant vaccines: 1.68 million yuan, up 39.62% year-on-year - Pet vaccines: 10.07 million yuan, up 49.65% year-on-year - Chemical drugs: 124 million yuan, up 20.94% year-on-year - Pet chemical drugs: 8.37 million yuan, up 9.99% year-on-year - Pet health products: 128.14 million yuan, up 124.47% year-on-year [2] - The new production base in Nanjing has been fully operational, leading to a nearly 60% increase in sales revenue from high-pathogenic avian influenza vaccines [2] - The company continues to implement a dual-channel marketing strategy for pet products, with online sales increasing by over three times [2] Group 3: Cost Control and R&D - The company's gross margin was 59.76%, a decrease of 3.42 percentage points year-on-year, while the net profit margin was 20.77%, down 5.47 percentage points year-on-year [3] - The company received 8 new veterinary drug registration certificates and 4 invention patent authorizations in H1 2025, indicating strong R&D capabilities [3] - Despite the decrease in margins, the company maintained a high level of R&D investment while enhancing cost control through economies of scale [3] Group 4: Future Outlook and Valuation - The company maintains a profit forecast of 178 million yuan, 197 million yuan, and 232 million yuan for 2025, 2026, and 2027 respectively, with corresponding EPS of 0.52, 0.57, and 0.67 yuan [3] - The current stock price corresponds to PE ratios of 28.70, 26.02, and 22.04 for the next three years, indicating a reasonable valuation range compared to peer companies [3] - The company's leading R&D innovation capabilities suggest potential for future valuation expansion [3]